BR112018001260A2 - mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição. - Google Patents

mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.

Info

Publication number
BR112018001260A2
BR112018001260A2 BR112018001260A BR112018001260A BR112018001260A2 BR 112018001260 A2 BR112018001260 A2 BR 112018001260A2 BR 112018001260 A BR112018001260 A BR 112018001260A BR 112018001260 A BR112018001260 A BR 112018001260A BR 112018001260 A2 BR112018001260 A2 BR 112018001260A2
Authority
BR
Brazil
Prior art keywords
composition
freeze
aqueous mixture
immunizing
preparing
Prior art date
Application number
BR112018001260A
Other languages
English (en)
Inventor
BOURLES Erwan
Mathot Frédéric
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112018001260A2 publication Critical patent/BR112018001260A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se à formulação de vetores adenovirais em uma mistura aquosa ou composição seca por congelamento na presença de açúcar amorfo e baixa concentração de sal, a sua formulação bem como a um método para a obtenção da composição seca.
BR112018001260A 2015-07-23 2016-07-20 mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição. BR112018001260A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513010.7A GB201513010D0 (en) 2015-07-23 2015-07-23 Novel formulation
PCT/EP2016/067280 WO2017013169A1 (en) 2015-07-23 2016-07-20 Pharmaceutical composition comprising an adenoviral vector

Publications (1)

Publication Number Publication Date
BR112018001260A2 true BR112018001260A2 (pt) 2018-09-11

Family

ID=54106515

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001260A BR112018001260A2 (pt) 2015-07-23 2016-07-20 mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.

Country Status (11)

Country Link
US (1) US10722470B2 (pt)
EP (1) EP3325016B1 (pt)
JP (1) JP6797891B2 (pt)
CN (1) CN108025081B (pt)
AR (2) AR105401A1 (pt)
BE (1) BE1023537B1 (pt)
BR (1) BR112018001260A2 (pt)
CA (1) CA2992922A1 (pt)
GB (1) GB201513010D0 (pt)
MX (1) MX2018001006A (pt)
WO (1) WO2017013169A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11047534B2 (en) 2016-01-28 2021-06-29 EcoSense Lighting, Inc. Multizone mixing cup illumination system
CA3079043A1 (en) * 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
EP3720500A4 (en) * 2017-12-05 2021-08-25 Applied Genetic Technologies Corporation FORMULATION OPTIMIZATION FOR VIRAL PARTICLES
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
WO2019202083A1 (en) * 2018-04-20 2019-10-24 Laboratorio Reig Jofré, S.A. Stable adenovirus compositions
EP3587581A1 (en) * 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
CN109055432B (zh) * 2018-08-16 2020-10-13 南京科佰生物科技有限公司 慢病毒感染试剂及其制备方法与应用
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
EP4216996A1 (en) * 2020-09-24 2023-08-02 Nant Holdings IP, LLC Vaccine compositions for mucosal immune response
EP4243790A1 (en) * 2020-11-16 2023-09-20 BioNTech SE Enhanced formulation stabilization and improved lyophilization processes
CN114903922B (zh) * 2021-02-09 2024-04-26 武汉博沃生物科技有限公司 包含腺病毒的医药配制品及其保存方法
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CN115554418B (zh) * 2022-11-22 2023-04-14 四川至善唯新生物科技有限公司 一种重组腺相关病毒载体的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CN107723298A (zh) * 2004-01-23 2018-02-23 Msd意大利有限公司 黑猩猩腺病毒疫苗载运体
KR20070045244A (ko) * 2004-08-12 2007-05-02 쉐링 코포레이션 안정한 페길화된 인터페론 제형
WO2007062040A1 (en) * 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
BR112012025047A2 (pt) * 2010-03-31 2016-06-21 Stabilitech Ltd formulações líquidas estabilizadas
ES2630012T3 (es) * 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) * 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
WO2015040234A1 (en) * 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
GB201701239D0 (en) * 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation

Also Published As

Publication number Publication date
JP2018521078A (ja) 2018-08-02
JP6797891B2 (ja) 2020-12-09
GB201513010D0 (en) 2015-09-09
CN108025081B (zh) 2021-11-02
EP3325016A1 (en) 2018-05-30
CA2992922A1 (en) 2017-01-26
EP3325016C0 (en) 2023-12-20
AR105401A1 (es) 2017-09-27
EP3325016B1 (en) 2023-12-20
MX2018001006A (es) 2018-06-06
BE1023537A1 (fr) 2017-04-26
BE1023537B1 (fr) 2017-04-26
US20180214379A1 (en) 2018-08-02
AR121079A2 (es) 2022-04-13
US10722470B2 (en) 2020-07-28
CN108025081A (zh) 2018-05-11
WO2017013169A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
BR112018001260A2 (pt) mistura aquosa, composição seca por congelamento, e, métodos para imunizar um indivíduo humano e para preparar uma composição.
BR112017008284A2 (pt) bifidobactérias ativadas e métodos para uso das mesmas
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
MY192226A (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
UY34995A (es) Formulaciones de anticuerpo y proteína
BR112015032918A8 (pt) células encapsuladas liofilizadas, métodos para sua liofilização e para sua preparação, seus usos, e composições
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112017012210A2 (pt) solução conservante de célula, uso da mesma e método de produção de solução conservante de célula
BR112016006326A2 (pt) formulação seca de uma vacina, uso de uma formulação seca, método para fabricação de uma formulação seca, e, vacina
BR112017005997A2 (pt) método
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EP3341498A4 (en) VIRTUAL INFERENCE OF PROTEIN ACTIVITY BY REGULON ENHANCEMENT ANALYSIS
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.